tbuckley/cabot-search huggingface dataset:
Abstract 1057: MRTF-A and MRTF-B Mediate Redundant Functions Required for Cardiac Development
Authors: Jian Li, Xiaohong Zhu, Lan Cheng, Minmin Lu, Mary Chen, Michael S Parmacek
Journal: Circulation (2006)

Myocardin and the myocardin-related transcription factors (MRTFs) -A and -B are transcriptional coactivators that have been implicated in cytoskeletal signaling and vascular development. Myocardin null mice die at embryonic day (E)10.5 and demonstrate no evidence of vascular smooth muscle cell (SMC) differentiation. MRTF-B null mice generally die at birth from a spectrum of cardiac outflow tract defects related to failure of the cardiac neural crest to differentiate into SMCs. To determine the function of MRTF-A in vivo, the MRTF-A gene was targeted in embryonic stem cells and MRTF-A null (−/−) mice were generated and characterized. Surprisingly, MRTF-A null mice were phenotypically indistinguishable from their control littermates without obvious cardiovascular defects. Therefore, MRTF-A−/− and MRTF-B+/− mice were intercrossed to determine whether these related transcription factors mediate redundant functions in the cardiovascular system. Compound heterozygotes (MRTF-A+/−/MRTF-B+/−) were born in the expected Mendelian ratio, but they exhibited a persistent ventricular septal defect (VSD). By contrast, 50% of MRTF-A−/−/MRTF-B+/− mice died between E14.5 and birth from heart failure. Histological examination of their hearts revealed near total obliteration of the ventricular cavities from proliferating cardiomyocytes. Finally, compound homozygotes (MRTF-A−/−/MRTF-B−/−) survived only to E9.5 exhibiting a severe block in looping morphogenesis. Taken together, these data reveal that MRTF-A and -B mediate partially overlapping, and redundant, functions required at multiple distinct stages of embryonic heart development. These data serve to identify MRTF-A and -B and genes regulated by these two related transcriptional co-activators in the pathogenesis of common forms of congenital heart disease.
Abstract 10322: Impact of Cryoablation on Esophageal Injury in a Canine Model
Authors: Hung-Kei Li, Susan B Johnson, Ning Zhong, Eduardo A Bonin, Mark D Topazian, Douglas L Packer
Journal: Circulation (2010)

Introduction: Balloon cryoablation of pulmonary veins (PVs) has emerged as a promising technique for the isolation of potentially arrhythmogenic substrate. Whether cryoablation is likely to create ...
Abstract 17291: Fractionated Atrial Electrograms Recorded During Sinus Rhythm: Is There a Difference Between Patients with Atrial Fibrillation and Controls?
Authors: Laszlo Saghy, Robert Pap, David J Callans, Fermin Garcia, David Lin, Michael Riley, Francis E Marchlinski, Steven J Kim, Edward p Gerstenfeld
Journal: Circulation (2010)

Introduction: Ablation of atrial fibrillation (AF) may require adjunctive substrate modification. Recently, fractionated atrial electrograms recorded during sinus rhythm (SRF) have been suggested a...
NF-κB Pathway Mutations Modulate Cell Survival and Ibrutinib Response In Chronic Lymphocytic Leukemia
Authors: Reina Improgo, Grace Tiao, Adam Kiezun, Yaoyu Wang, Lillian Werner, Carrie Sougnez, Bethany Tesar, Stacey M Fernandes, Alexander R. Vartanov, Kevin Hoang, Donna S. Neuberg, Gad Getz, Jennifer R. Brown
Journal: Blood (2013)
Abstract 3402: Improvement of Left Ventricular Regional Function and Reverse Remodeling in Heart Failure Patients Received Cardiac Contractility Modulation Therapy-A Comprehensive Assessment by Real-Time 3D Echocardiogram and Tissue Doppler Imaging
Authors: Yat-sun Chan, Qing Zhang, Jeffrey W Fung, Anna K Chan, Chun-yan Ma, Cheuk-man Yu
Journal: Circulation (2007)

Introduction: Cardiac Contractility Modulation (CCM) is a new form of device based therapy for advance heart failure patient even with normal QRS width and therefore not a candidate for cardiac resynchronization therapy. Previous studies showed that CCM improved left ventricular (LV) ejection fraction (EF) and clinical parameters of heart failure patients. However data from comprehensive echocardiographic assessment and structural reverse remodeling is lacking. Methods: 18 patients (mean age: 56±9 years, 15 males) with NYHA class III heart failure, QRS &lt;120msec and already on optimal medical therapy received CCM. Real-time 3D echocardiography (RT3DE) (IE33, Philips) and tissue Doppler imaging (TDI) (Vivid 7, GE) were performed at baseline and 3 months after CCM. Results: LV reverse remodeling with reduction in volumes and gain in EF was observed by RT3DE at 3 months. TDI also showed improvement of regional systolic function resulting in an increase in peak systolic velocity by measuring 12 (Mean Sm-12) or 6 basal (Mean Sm-6) LV segments. LV filling pressure estimated by E/E’ was also favorably reduced (Table ). Conclusions: CCM improves both global and regional LV contractility and reduces filling pressure leading to LV reverse remodeling. Table
Abstract 318: Sildenafil Improves Cardiac Function and Inhibits Protein Kinase C-{alpha} Translocation in Advanced-established Hypertrophy
Authors: Takahiro Nagayama, Eiki Takimoto, Norimichi Koitabashi, Djahida Bedja, Kathleen L Gabrielson, David A Kass
Journal: Circulation (2007)

Background: Sildenafil (SIL) inhibits cyclic GMP-specific phosphodiesterase 5A (PDE5A), and prevents cardiac hypertrophy and dysfunction in mice subjected to pressure overload. Its ability to suppr...
Evidence that sustained growth suppression of intestinal anaerobic bacteria reduces the risk of acute graft-versus-host disease after sibling marrow transplantation
Authors: DW Beelen, E Haralambie, H Brandt, G Linzenmeier, KD Muller, K Quabeck, HG Sayer, U Graeven, HK Mahmoud, UW Schaefer
Journal: Blood (1992)
Glucose tolerance testing in women with premenstrual syndrome
Authors: K D Denicoff, C Hoban, G N Grover, D R Rubinow
Journal: American Journal of Psychiatry (1990)

Glucose tolerance tests (GTTs) were administered to 11 women with premenstrual syndrome (PMS) to ascertain whether the patients had abnormalities of glucose tolerance, to determine whether such abnormalities were related to menstrual cycle phase, and to compare the symptoms during the GTT with the PMS symptoms experienced in the luteal phase. Two GTTs were performed for each patient, one during the late follicular phase and one during the late luteal phase. Although many patients experienced symptoms of hypoglycemia during the GTT, the hypoglycemia symptoms were not specific to the luteal phase and did not resemble the patients' PMS symptoms.
Surveillance of antibiotic resistance in Salmonella
Authors: A Brisabois, I Cazin, J Breuil, E Collatz
Journal: Eurosurveillance (1997)

The World Health Organisation has recently pointed out an alarming increase in the incidence of antibiotic resistant strains of Salmonella, which are due to the use of antibiotics in intensive breeding. In France, until recent years, no or few cases of a
Abstract 15157: AT1 Receptor-Activated Toll-Like Receptor 4 in the Brainstem Causes Sympathoexcitation in Mice With Heart Failure
Authors: Kiyohiro Ogawa, Yoshitaka Hirooka, Takuya Kishi, Kenji Sunagawa
Journal: Circulation (2010)

Background: Previous studies suggest that heart failure (HF) is associated with sympathoexcitation due to oxidative stress in the brain induced by AT1 receptors (AT1R). In the brain, oxidative stress occurs upstream of inflammatory signaling pathways mediated by toll-like receptor 4 (TLR4). Hypothesis: AT1R-induced sympathoexcitation is mediated by TLR4 in the brainstem of HF model , and if so, the inflammation in the brain is associated with sympathoexcitation. Method and Results: As a model of HF, the left coronary artery was ligated to induce a large myocardial infarction and subsequent HF in ICR mice. On day 10 after the left coronary artery ligation, we initiated 14-day chronic intracerebroventricular (ICV) infusion of losartan (CHF-Los) or vehicle (CHF-Veh) via osmotic minipumps. Expression of TLR4 in the brainstem determined by Western blot analysis was significantly higher in HF mice than in sham mice (1.06±0.04 vs 0.56±0.11, n=5 for each, P<0.05) and significantly lower in CHF-Los than in CHF-Veh...
Neurologic Disorders in Renal Failure
Authors: Neil H. Raskin, Robert A. Fishman
Journal: New England Journal of Medicine (1976)

Maintenance hemodialysis and kidney transplantation have changed the natural history of renal failure and its clinical manifestations. This result is particularly striking for neurologic involvement, in which new syndromes have been defined, as a consequence of both increased longevity and the complications of therapy. This review will summarize current views of uremic encephalopathy and its pathophysiology, uremic neuropathy, and the neurologic complications of dialysis and renal transplantation.The neurologic consequences of uremia are similar in many ways to the effects on the central nervous system of other metabolic and toxic disorders. In uremia, as in portal–systemic encephalopathy, hypoxemia, water intoxication, . . .
Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group
Authors: R Hehlmann, H Heimpel, J Hasford, HJ Kolb, H Pralle, DK Hossfeld, W Queisser, H Loffler, B Heinze, A Georgii
Journal: Blood (1993)
The alpha-globin gene adjacent to the gene for HbQ-alpha 74 Asp replaced by His is deleted, but not that adjacent to the gene for HbG- alpha 30 Glu replaced by Gln; three-fourths of the alpha-globin genes are deleted in HbQ-alpha-thalassemia
Authors: LE Lie-Injo, AM Dozy, YW Kan, M Lopes, D Todd
Journal: Blood (1979)
Abstract 1190: Association of Smoking Status with Incidental Metabolic Syndrome in Men; a 3-year Follow-up Study
Authors: Byung Jin Kim, Ki Chul Sung, Bum Soo Kim, Jin Ho Kang, Man Ho Lee
Journal: Circulation (2008)

Although cigarette smoking has been known to be a risk factor for increased insulin resistance and other metabolic abnormalities, there is no data to assess the association of smoking status with incidental metabolic syndrome (MS). We investigated the incidence of MS and assessed the effect of smoking status on incidental MS. The subjects were 4542 men (median age of 44 years) without MS who were followed for an average of 3 years. For analysis, smoking status was divided into 4 groups, non-smokers, new-smokers, ex-smokers, or sustained-smokers, according to smoking status at baseline and 3-year follow-up. The overall incidence of MS was 10.6%; the incidence of MS in each group was 8.0% in the non-smokers, 7.1% in the new-smokers, 17.1% in the ex-smokers, and 13.9% in sustained-smokers (p&lt;0.0001). In a multivariate logistic regression model (Model 1) adjusting for age, baseline weight, alcohol consumption, exercise, and baseline number of MS components, sustained-smokers and ex-smokers predicted a significant increased odds for incidental MS of 1.68 (95% CI 1.33–2.12) and 2.43 (95% CI 1.80 –3.29), respectively, as compared with non-smokers. When weight change is included (Model 2), the odds ratios were attenuated (1.54[1.21–1.95] ; 1.87[1.37–2.56], respectively). Among sustained-smokers, the odds ratio for incidental MS increased according to the amount or the duration of smoking. Furthermore, ex-smokers had a significant increased odds for incidental MS of 1.45 (95% CI 1.06 –1.98), compared with continuous-smokers (model 1). This was no longer significant after including weight change (model 2). In conclusion, either sustained smoking or smoking cessation in 3 years is a risk factor for incidental metabolic syndrome in men, independent of weight change, as compared with non-smoking. Also smoking cessation in 3 years might be a higher risk factor for incidental MS than sustained smoking. Our study indicates that weight control in men, especially with smoking cessation is critical to attenuate the additional risk for incidental MS.
Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients
Authors: Jose I. Chacón, Manuela Mollejo, Enriqueta Muñoz, Patricia Algara, Marisol Mateo, Luis Lopez, Jesús Andrade, Iciar Garcı́a Carbonero, Beatriz Martı́nez, Miguel A. Piris, Miguel A. Cruz
Journal: Blood (2002)
Pericardial Delayed Hyperenhancement With CMR Imaging in Patients With Constrictive Pericarditis Undergoing Surgical Pericardiectomy
Authors: Andrew O. Zurick, Michael A. Bolen, Deborah H. Kwon, Carmela D. Tan, Zoran B. Popovic, Jeevanantham Rajeswaran, E. Rene Rodriguez, Scott D. Flamm, Allan L. Klein
Journal: JACC. Cardiovascular imaging (2011)
Pulmonary Vascular Effects of Fat Emulsion Infusion in Unanesthetized Sheep
Authors: Charles R. McKeen, Kenneth L. Brigham, Ronald E. Bowers, Thomas R. Harris
Journal: Journal of Clinical Investigation (1978)

Pulmonary diffusing capacity and arterial blood Po2 decrease in humans when 10% fat emulsion is infused. To study its effects on the pulmonary circulation and lung fluid balance, we infused 0.25 g/kg × h of a 10% fat emulsion (Intralipid, Cutter Laboratories, Inc., Berkeley, Calif.) into an awake sheep lung lymph preparation. The emulsion caused a sustained increase in pulmonary artery pressure to approximately twice base line with little change in left atrial pressure. PaO2 decreased an average 13 torr and lung lymph flow increased two- to threefold. Lymph/plasma total protein concentration fell as lymph flow increased; the magnitude of the lymph/plasma protein decrease was similar to that reported previously when lung vascular pressures were mechanically elevated. Heparin infusion (loading dose = 4,000 U, maintenance dose = 2,000 U/h) cleared the serum of triglycerides but did not alter the response to fat emulsion. Indomethacin infusion (loading dose = 5 mg/kg, maintenance dose = 3 mg/kg × h) blocked the rise in pulmonary artery pressure, the increase in lung lymph flow, and the fall in PaO2. Neither extravascular lung water nor [14C]urea lung vascular permeability surface area products were altered by fat emulsion infusion. We conclude that fat emulsion infusion in sheep increases lung microvascular filtration by increasing vascular pressures, but has no effect on vascular permeability. Since the effects are blocked by indomethacin, they may be prostaglandin mediated.
Abstract 14720: Novel Sodium Channel Voltage Sensor Mutation Leading to Unique Escape Capture Bigeminy Phenotype and Left Ventricular dysfunction
Authors: Krishnakumar Nair, Roman Pekhletski, Elod Szabo, Talha Farid, Kwaku Poku, Louise Harris, Peter Backx, Kumaraswamy Nanthakumar
Journal: Circulation (2010)

Introduction: Voltage sensor mutations may cause hypokalemic periodic paralysis. We report a sodium channel voltage sensor mutation producing dilated cardiomyopathy and a spectrum of arrhythmias wi...
Abstract 13865: Improvement of Guideline Use in Young Hearts Strong Starts, a Cluster Randomized Trial of Cardiovascular Prevention in Pediatric Offices
Authors: Kenneth A LaBresh, Suzanne Lazorick, Robert Furberg, Adolfo Ariza, Lauren Whetstone, Connie Hobbs, Janet de Jesus, Randall Bender, Ilse Salinas, Helen Binns
Journal: Circulation (2013)

Objective: To evaluate the impact of a multifaceted intervention for assessment, Interpretation and treatment of BMI, BP and tobacco exposure and use during routine well child visits, based on the ...
Abstract 17194: Maintenance of Sinus Rhythm Following AF Ablation May Preclude ICD Implant for Primary Prevention of Sudden Death: a Pilot Study
Authors: Indiresha Ramachandra, Ashish Bhimani, Shervin Sadrpour, Peter Milolajczak, Firas ELSabbagh, Sergey Vitebskiy, Cakukev Ivan, Robert Goldstein, Judith Mackall, Albert Waldo, Mauricio S Arruda
Journal: Circulation (2011)

Background: Atrial fibrillation (AF) ablation is safe and efficacious in pts with AF and impaired LV systolic function. Furthermore, maintenance of sinus rhythm (SR) following AF ablation in pts with CHF has favorable impact on LVEF, functional status and quality of life. Current guidelines recommend an implantable cardiac defibrillator (ICD) for primary prevention of sudden death in pts with LVEF ≤ 35% on optimal medical therapy. Hypothesis: This pilot study was designed to test the following hypothesis: “SR after AF ablation in pts with AF and LVEF ≤ 35% will improve LV function and preclude an ICD”. Methods: Forty-nine consecutive pts with AF and impaired LV function (including pts with LVEF ≤ 35%) and controlled ventricular rates underwent AF ablation (electrogram-guided pulmonary vein isolation + linear and CFAE ablation if needed) before considering an ICD implant. All pts were rate controlled and on optimal medical therapy for CHF prior to AF ablation. All pts had strict clinical and rhythm monitoring until repeat LV function assessment post ablation. Results: Twenty-three pts had LVEF ≤ 35% (Group 1) and 26 pts had LVEF 36-50% (Group 2). Similar to other studies, 18 of 26 (69%) pts in Group 2 had an improved LVEF and no hospitalization post AF ablation. Importantly, 16 pts (70%) in Group 1 had improvement in mean LVEF from 30% to 44% which precluded an ICD implant. Eight of these 16 pts (50%) normalized their EF. Recurrent AF post ablation and myocardial scar due to ischemic cardiomyopathy likely accounted for lack of LVEF improvement in some pts. These pts received an ICD implant if their LVEF remained ≤ 35%. The only significant complication was 1 TIA in 1 pt. Conclusions: Maintenance of SR following AF ablation in pts with impaired LV systolic function improves LVEF. This pilot study suggests AF ablation may be considered prior to an ICD implant, particularly in pts with NICM. This pilot study warrants a prospective, multi-center investigation.
Abstract 14010: ST Segment Shortening Without QT Interval Shortening is a Unique and Novel Marker of Asymmetric Cardiac Sympathetic Activation
Authors: Olujimi A Ajijola, Rafael J Ramirez, Michael Laks, Wei Zhou, Aman Mahajan, Kalyanam Shivkumar
Journal: Circulation (2011)

Introduction: Sympathetic nerve stimulation results in intra-myocardial norepinephrine release with subsequent myocyte action potential duration (APD) shortening. Heterogeneity in this response (as...
Abstract 403: BMPER Is an Angiogenic Modulator that is Regulated by KLF-15 and FoxO3A and Controls Bone Morphogentic Protein Activity
Authors: Thomas Helbing, Jennifer Heinke, Franziska Volkmar, Leonie Wehofsits, Kim-Miriam Baar, Philipp Diehl, Christoph Bode, Cam Patterson
Journal: Circulation (2008)

BMPER (bone morphogenetic protein [BMP] endothelial precursor cell derived regulator) is an extracellular protein, that interacts with BMPs and thereby modulates BMP dependent vasculogenesis and angiogenesis. Our previous observations suggest a complex regulation of BMPER expression. During embryogenesis BMPER is expressed at the time and at sites of vasculogenesis, whereas in the adult organism it is expressed in heart, lung and skin. Methods and Results: We have cloned the mouse BMPER promoter and appropriate deletion constructs into pGL3 to regulate luciferase expression. As predicted in silicio, we found that Sp1 and Sp1-like transcription factors such as the krueppel-like factors (KLFs) regulate BMPER transcription. KLF-15 resulted in a 4.5 fold upregulation. Accordingly, BMPER expression was inhibited by the Sp-1/SP-1 like inhibitor mitramycin A. Site specific mutation of a proximal KLF-15 binding site reduced the effect of KLF-15 on BMPER expression. Along the same lines, knock down of KLF-15 in HUVEC by siRNA reduced BMPER expression. The transactivating effect of KLF-15 could be competed away by coexpression of Sp-1 suggesting that both factors may compete for the same binding site in the BMPER promoter. In EMSA, an oligo representing a well characterized KLF-15 binding site in the AceCs2 promoter but not an oligo encoding for a NFkappa-B site competed with the oligo coding for the KLF-15 site in the BMPER promoter. In contrast FoxO3A, a member of the FoxO family of transcription factors, serves as an inhibitor of BMPER expression, as shown by gain and lack of FoxO3A experiments. Additionally, we found that BMPER stimulates angiogenesis in a BMP-4 dependent manner in several in vitro and in vivo assays. Vice versa, BMPER is necessary for BMP-4 to exert is angiogenic activity on endothelial cells. Conclusion: BMPER is upregulated by KLF-15 and inhibited by FoxO3a. BMPER has angiogenic activity and is a key modulator of the BMP pathway.
UN treaty to cut most toxic pollutants imminent
Authors: Judy Jones
Journal: BMJ (2000)

A global treaty to protect human health from the most toxic persistent organic pollutants is to be negotiated by more than 120 countries in Johannesburg next month. The United Nations Environment Programme is seeking agreement for the treaty to reduce or eliminate the 12 persistent organic pollutants that the programme regards as the most threatening to future generations.

These pollutants …
Abstract 5923: Increased Frequency of High Heart Rate Episodes is Associated with Heart Failure Decompensation
Authors: Yong K Cho, Dwight W Reynolds, Robin E Germany, Fred J Kueffer, Robert T Taepke, Robert C Bourge, Tom D Bennett
Journal: Circulation (2008)

The time course of cardiac arrhythmia occurrences and heart failure decompensation (HFD) events has not been well understood. To determine whether high heart rate (HHR) episodes occur more frequently prior to HFD events, the temporal relationship between HHR episodes and HFD events was analyzed from the COMPASS-HF study. The COMPASS-HF study included 274 NYHA class III-IV patients with an implantable hemodynamic monitor (IHM). In addition to monitoring hemodynamic status, the IHMs were set up to detect and store HHR episodes defined as a sensed ventricular HR &gt; 150 bpm for at least 12 of 16 consecutive cardiac cycles. The number of IHM detected HHR episodes during the first 6-months of enrollment in the study was compared to HFD events by two methods: within patients, by comparing HHR episode rate before and after a HFD event in patients with a single HFD event and between patients, by comparing HHR episode rate in patients with HFD events (prior to the first HFD event) to HHR episode rate in patients without HFD events. For those patients with one HFD event (n = 53 patients), HHR episode rates (# of HHR episodes/day) were 0.36 ± 0.82 and 0.05 ± 0.11 (p &lt; 0.01) before and after the HFD event, respectively. Monitoring durations were 94 ± 4 days for before the HFD event and 91 ± 50 days for after the event. HHR episode rates were 0.30 ± 0.77 and 0.19 ± 0. 61 (p &lt; 0.01) for patients with HFD events (n = 104 patients) and without HFD events (n = 170 patients), respectively. Monitoring durations prior to the first HFD event, and in patients without HFD events were 77 ± 46 days and 178 ± 41 days. IHM detected HHR episodes occurred seven times more frequently prior to HFD events than after HFD events. While the IHM could not differentiate the types of HHR rhythms, these data demonstrate a clear association between the rate of HHR episodes and HFD events. The cause and effect relation remains to be more clearly defined.
Abstract 13763: Exercise Test Results Have Prognostic Value in Chidren with Dilated Cardiomyopathy
Authors: Alessandro Giardini, Matthew Fenton, Graham Derrick, Michael Burch
Journal: Circulation (2010)

Introduction: Children with dilated cardiomyopathy (DCM) are at risk of death due to worsening heart failure and sudden arrhythmias. Cardiopulmonary exercise test (CPET) is prognostically important...